This study is designed to evaluate the repeat-dose safety and effectiveness of a
bronchodilator inhaler relative to placebo (inactive drug inhaler) in children aged 4-11
years with asthma. The dosing period lasts three weeks and starts following a three-week
run-in period.
Minimum age: 4 Years.
Maximum age: 11 Years.
Gender(s): Both.
Little Rock Allergy and Asthma, Little Rock, Arkansas 72205-4565, United States
Allergy & Asthma Associates of Santa Clara Valley Research Center, San Jose, California 95117, United States
Allergy & Asthma Specialist Medical Group, Huntington Beach, California 92647, United States
Colorado Allergy and Asthma Centers, PC, Englewood, Colorado 80112, United States
Colorado Allergy and Asthma Centers, PC, Lakewood, Colorado 80401, United States
Colorado Allergy and Asthma Centers, PC, Denver, Colorado 80230, United States
William Storms Medical Research, Colorado Springs, Colorado 80907, United States
Southern Allergy & Asthma, PC, Savannah, Georgia 31405, United States
Sneeze, Wheeze & Itch Associates, Inc., Normal, Illinois 61761, United States
Clinical Research Institute, Minneapolis, Minnesota 55402, United States
The Asthma & Allergy Center, PC, Papillion, Nebraska 68046, United States
Allergy and Respiratory Center, Canton, Ohio 44718, United States
Allergy, Asthma & Clinical Research Center, Oklahoma City, Oklahoma 73120, United States
Pediatric Pulmonary Associates of North Texas, Dallas, Texas 75230, United States